Biohaven Ltd. (BHVN) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

34/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

65

Gaining

Sentiment

44

Mixed

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Vladimir Coric
Listed since: Sep 23, 2022
Employees: 274

Market position

Volume: 196.73K; 0.08× average
Average volume: 2.57M; Average daily volume
Market cap: 2.07B USD
Beta: 3.16; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.27B USD
EV / EBITDA: -1.75×
Earnings yield: -60.80%
Free cash flow yield: -50.21%

Profitability & efficiency

Return on equity: -1418.85%
Return on assets: -163.66%
Return on invested capital: -218.41%

Financial health

Current ratio: 3.18×

Earnings

EPS beat rate: 18%; 2 beats, 7 misses, 2 met estimates
Average EPS surprise: -22.01%; 11 comparable reports
Latest EPS result: -0.91; Estimate -0.76 · Miss by 19.58%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

25 ratings

Strong buy00%

Buy1768%

Hold728%

Sell14%

Strong sell00%

BHVN news

prnewswire.comAug 10, 2026

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results

First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and…

Read source

prnewswire.comAug 6, 2026

Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors

Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to Biohaven as the company advances AI-enabled approaches to drug development NEW HAVEN, Conn., Aug. 6, 2026 /PRNewswire/ --…

Read source

prnewswire.comJul 27, 2026

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd.

Read source

prnewswire.comJul 20, 2026

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show early tumor…

Read source

seekingalpha.comJul 13, 2026

Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk

Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets. Today, I think opakalim's pivotal epilepsy readout is probably the most important near-term catalyst that could…

Read source